In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emergent BioSolutions, Inc.

https://www.emergentbiosolutions.com/

Latest From Emergent BioSolutions, Inc.

US FDA Serves Notice: Approval Of OTC Naloxone Could Close Prescription Sales

Agency signals assurance about making naloxone available OTC, so much so that firms with approved NDAs for Rx products should prepare for an all-nonprescription market. After offering model label to spur OTC switch NDAs, FDA notice about OTC assessment is second unprecedented step on its naloxone journey since opioid crisis declared a public health emergency in 2017.

Drug Approval Standards FDA

US FDA Serves Notice: Approval Of OTC Naloxone Could Close Prescription Sales

Agency signals assurance about making naloxone available OTC, so much so that firms with approved NDAs for Rx products should prepare for an all-nonprescription market. After offering model DFl to spur OTC switch NDAs, FDA notice about OTC assessment is second unprecedented step on its naloxone journey since opioid crisis declared a public health emergency in 2017.

Drug Approval Standards FDA

Indivior Looks To Cement Addiction Drug Leadership With Opiant Buy

Some observers believe Indivior is paying a very reasonable price to get hold of OPNT003, an intranasal formulation of the opioid antagonist nalmefene, which is expected to be filed with the US FDA by the end of the year.

M & A Business Strategies

As Vaccines Pipeline Gushes, Complex Communication Challenges Loom

CDC Advisory Committee on Immunization Practices prepares for expected US FDA approvals of new vaccines to prevent respiratory syncytial virus in older adults, chikungunya and dengue and clarified recommendations for high-valent pneumococcal vaccines.

Advisory Committees Vaccines
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Adapt Pharma Limited
    • Aptevo Therapeutics
    • BioPort Corporation
    • Cangene Corporation
    • Trubion Pharmaceuticals, Inc.
    • PaxVax Corporation
UsernamePublicRestriction

Register